A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03656536 |
|
Recruitment Status :
Recruiting
First Posted : September 4, 2018
Last Update Posted : November 17, 2022
|
Sponsor:
Incyte Corporation
Information provided by (Responsible Party):
Incyte Corporation
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | October 26, 2027 |
| Estimated Study Completion Date : | July 27, 2028 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):